3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
3
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Hodgkin Disease
2
Fallopian Tube Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Glioma
1
Endometrial Neoplasms
1
Diffuse Intrinsic Pontine Glioma
1
Advanced Malignant Solid Neoplasm
1
Interventions
Temozolomide
41
Radiotherapy
15
Magnetic Resonance Spectroscopy
12
Surgical Procedures, Operative
10
Bevacizumab
10
Irinotecan
9
Radiation
8
Nivolumab
7
Carmustine
7
Specimen Handling
6
Radiosurgery
6
Carboplatin
6
ribociclib
5
O(6)-benzylguanine
5
Imiquimod
5
IL13-PE38
5
Flucytosine
5
Filgrastim
5
Erlotinib Hydrochloride
5
Cyclophosphamide
5
Aminolevulinic Acid
5
vandetanib
4
sargramostim
4
Topotecan
4
Lomustine
4
Imatinib Mesylate
4
Etoposide
4
Craniotomy
4
vocimagene amiretrorepvec
3
temsirolimus
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Glioma
×
Pharmacogenomic Variants
×
Clear all
NCT01165333
2026-03-16
CILENT
Centre Oscar Lambret
Phase 1
Completed
32 enrolled